GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: RXII
Buy $6

galena biopharma (NASDAQ: GALE) reiterated to Buy with price target $6 by Roth Capital

Tuesday,  Nov 10, 2015  8:25 AM ET by Lynn Gilbert

Roth Capital reiterated galena biopharma (NASDAQ: GALE) to Buy with price target
$6. Previously, Roth Capital rated galena biopharma (NASDAQ: GALE) to Buy with price target $7 on 03/18/2014, when the stock price was valued at $2.82.

RXi Pharmaceuticals Corporation (RXi) is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid interference (RNAi) for the treatment of human diseases. The Company is focused on internal research and development programs on certain inflammatory and metabolic diseases, and to pursue other therapeutic areas with potential partners. RXi commenced operations after CytRx Corporation contributed to the Company its portfolio of RNAi therapeutic assets, which consisted primarily of RNAi licenses and related intellectual property, and a nominal amount of equipment. As of December 31, 2008, the Company had not generated any revenues.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy